Drug Profile

Phenylephrine intravenous - Exela Sterile Medicines

Alternative Names: Phenylephrine hydrochloride - Avadel Pharmaceuticals; Vazculep

Latest Information Update: 17 Feb 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Eclat Pharmaceuticals
Developer Avadel Pharmaceuticals
Class Antihypotensives; Decongestants; Ethanolamines; Mydriatics; Phenethylamines; Skin disorder therapies; Small molecules; Urologics
Mechanism of Action Alpha 1 adrenergic receptor agonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Marketed Hypotension

Most Recent Events

12 Feb 2026 Avadel Pharmaceuticals has been acquired by Alkermes plc
01 Jul 2020 Exela Sterile Medicines acquires Phenylephrine intravenous from Avadel Pharmaceuticals
03 Jan 2017 Flamel Technologies completed its cross-border merger with Avadel Pharmaceuticals and is now called Avadel Pharmaceuticals

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com